Professional Documents
Culture Documents
DR. SALVADOR
GLUCOCORTICOIDS
CALCINEURIN INHIBITORS
Cyclosporine
Tacrolimus
CYCLOSPORINE
- Cyclosporine is a peptide antibiotic that appears to act at an early stage in the antigen receptor-induced differentiation of T cells and blocks their
activation
- binds to cyclophilin
- Cyclosporine and cyclophilin complex inhibits calcineurin (necessary for the activation of a T-cell-specific transcription factor called NF- AT, w/c
is involved in the synthesis of IL- 2
- absorbed drug is primarily metabolized by the P450 3A enzyme system in the liver
-
Clinical indications Adverse Effects
graft-versus-host disease after hematopoietic stem cell transplantation nephrotoxicity, hypertension, hyperglycemia, liver dysfunction,
kidney, pancreas, liver, and heart transplant hyperkalemia, altered mental status, seizures, and hirsutism
ophthalmic solution: dry eye syndrome increased incidence of lymphoma and other cancers due to its release
Inhaled cyclosporine: lung transplantation of TGF-
autoimmune disorders: uveitis, rheumatoid arthritis, psoriasis, and
asthma
TACROLIMUS
- (FK 506) is an immunosuppressant macrolide antibiotic produced by Streptomyces tsukubaensis.
- binds to the immunophilin FK-binding protein (FKBP) blocking calcineurin
- tacrolimus is 10100 times more potent than cyclosporine
-
Clinical Indications Adverse Effects
preventing rejection in solid-organ transplant patients even after failure nephrotoxicity, neurotoxicity, hyperglycemia, hypertension,
of standard rejection therapy hyperkalemia, and gastrointestinal complaints.
considered a standard prophylactic agent (usually in combination with
methotrexate or mycophenolate mofetil) for graft-versus-host disease.
Tacrolimus ointment: atopic dermatitis and psoriasis
pharmacology REVIEWER immunosuppressive agents
DR. SALVADOR
MYCOPHENOLATE MOFETIL
semisynthetic derivative of mycophenolic acid, isolated from the mold Penicillium glaucus.
inhibits T- and B-lymphocyte responses, including mitogen and mixed lymphocyte responses, probably by inhibition of de novo synthesis of purines.
Clinical Manifestations Adverse Effects
first-line drug for preventing or reducing chronic allograft vasculopathy Toxicities include gastrointestinal disturbances (nausea and vomiting,
in cardiac transplant recipients diarrhea, abdominal pain) headache, hypertension, and reversible
used as prophylaxis for and treatment of both acute and chronic graft- myelosuppression (primarily neutropenia).
versus-host diseases in hematopoietic stem cell transplant patients
THALIDOMIDE
sedative drug that was withdrawn from the market in the 1960s because of its disastrous teratogenic effects when used during pregnancy.
inhibits angiogenesis and has anti-inflammatory and immunomodulatory effects.
It inhibits tumor necrosis factor-alpha (TNF-), reduces phagocytosis by neutrophils, increases production of IL-10, alters adhesion molecule
expression, and enhances cell-mediated immunity via interactions with T cells.
Clinical Indications Adverse Effects
Thalidomide is currently used in the treatment of multiple myeloma at The most important toxicity is teratogenesis
initial diagnosis and for relapsed-refractory disease
CYTOTOXIC AGENTS
Azathioprine
Cyclophosphamide
Leflunomide
Hydroxychloroquine
Other cytotoxic agents
AZATHIOPRINE
- prodrug of mercaptopurine and, like mercaptopurine, functions as an antimetabolite
- Xanthine oxidase splits much of the active material to 6-thiouric acid prior to excretion in the urine
- produce immunosuppression by interfering with purine nucleic acid metabolism at steps that are required for the wave of lymphoid cell proliferation
that follows antigenic stimulation
Clinical Indications Adverse Effects
maintaining renal allografts and may be of value in transplantation of The chief toxic effect of azathioprine and mercaptopurine is bone
other tissues. marrow suppression,
Hepatic dysfunction, manifested by very high serum alkaline
phosphatase levels and mild jaundice
pharmacology REVIEWER immunosuppressive agents
DR. SALVADOR
CYCLOPHOSPHAMIDE
- alkylating agent cyclophosphamide is one of the most efficacious immunosuppressive drugs available
- MOA: destroys proliferating lymphoid cells but also appears to alkylate DNA and other molecules in some resting cells.
Clinical Indications Adverse Effects
In smaller doses: autoimmune disorders (including systemic lupus carries considerable risk of pancytopenia and hemorrhagic cystitis
erythematosus) and in patients with acquired factor XIII antibodies and
bleeding syndromes, autoimmune hemolytic anemia, antibody-induced
pure red cell aplasia, and Wegeners granulomatosis.
LEFLUNOMIDE
- inhibitor of pyrimidine synthesis
- orally active, and the active metabolite has a long half-life of several weeks
Clinical Indications Adverse Effects
only for rheumatoid arthritis at present elevation of liver enzymes with some risk of liver damage, renal
impairment, and teratogenic effects.
HYDROXYCHLOROQUINE
- antimalarial agent with immunosuppressant properties.
- It is thought to suppress intracellular antigen processing and loading of peptides onto MHC class II molecules by increasing the pH of lysosomal and
endosomal compartments, thereby decreasing T-cell activation.
Clinical Indications Adverse Effects
only for rheumatoid arthritis at present
IMMUNOSUPPRESSIVE ANTIBODIES
Antilymphocyte & Antithymocyte Antibodies
- ALG acts primarily on the small, long-lived peripheral lymphocytes that circulate between the blood and lymph
- As a result of the destruction or inactivation of T cells, an impairment of delayed hypersensitivity and cellular immunity occurs while humoral
antibody formation remains relatively intact
Clinical Indications Adverse Effects
ALG and ATG are useful for suppressing certain major compartments Local pain and erythema often occur at the injection site (type III
(ie, T cells) of the immune system and play a definite role in the hypersensitivity)
management of solid organ and bone marrow transplantation Complexes of host antibodies with horse ALG may precipitate and
localize in the glomeruli of the kidneys
Muromonab-CD3 (OKT3)
- blocks killing by cytotoxic human T cells and several other T-cell functions
Clinical Indications Adverse Effects
Treatment of acute renal allograft rejection and steroid-resistant acute NONE (as per Katzung)
cardiac and hepatic transplant rejection
pharmacology REVIEWER immunosuppressive agents
DR. SALVADOR
Immune Globulin Intravenous (IGIV)
- An approach of intravenous use of polyclonal human immunoglobulin
- immunoglobulin preparation (usually IgG) is prepared from pools of thousands of healthy donors, and no single, specific antigen is the target of the
therapeutic antibody.
Clinical Indications MOA
safe and effective in Kawasakis disease reduction of T helper cells
systemic lupus erythematosus and refractory idiopathic increase of regulatory T cells
thrombocytopenic purpura. decreased spontaneous immunoglobulin production,
Fc receptor blockade
increased antibody catabolism, and idiotypic-anti-idiotypic interactions
with pathologic antibodies.
B. Abatacept C. Alefacept
recombinant fusion protein composed of the extra- cellular domain of engineered protein consisting of the CD2-binding portion of leukocyte-
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) fused to hinge, function-associated antigen-3 (LFA-3) fused to a human IgG1 Fc region
CH2, and CH3 domains of human IgG1 (hinge, CH2, and CH3).
binds more tightly to CD80/86 than CD28 Clinical uses: treatment of patients with plaque psoriasis
Clinical uses: rheumatoid arthritis and juvenile idiopathic arthritis.
D. Basiliximab and Daclizumab E. Natalizumab
chimeric mouse-human IgG1 that binds to CD25, the IL-2 receptor humanized IgG4 monoclonal antibody that binds to the 4-subunit of
alpha chain on activated lymphocytes. 41 and 47 integrins expressed on the surfaces of all leukocytes
MOA: Both agents function as IL-2 antagonists, blocking IL-2 from except neutrophils, and inhibits the 4-mediated adhesion of
binding to activated lymphocytes, and are therefore leukocytes to their cognate receptor.
immunosuppressive. Clinical uses: treatment of patients with multiple sclerosis and Crohns
disease
pharmacology REVIEWER immunosuppressive agents
DR. SALVADOR
F. Omalizumab G. Tocilizumab
anti-IgE recombinant humanized monoclonal antibody that is recombinant humanized IgG1 that binds to soluble and membrane-
approved for the treatment of allergic asthma in adult and adolescent associated IL-6 receptors.
patients whose symptoms are refractory to inhaled corticosteroids Clinical uses: rheumatoid arthritis who are refractory to other anti-TNF-
MOA: blocks the binding of IgE to the high-affinity Fc receptor on biologicals.
basophils and mast cells, which suppresses IgE-mediated release of
type I allergy mediators such as histamine and leukotrienes
H. Ustekinumab
is a human IgG1 monoclonal antibody that binds to the p40 subunit
of IL-12 and IL-23 cytokines.
MOA: It blocks IL-12 and IL-23 from binding to their receptors,
therefore inhibiting receptor-mediated signaling in lymphocytes.
Clinical uses: moderate to severe plaque psoriasis.
OTHER MABs
Abciximab Denosumab
murine-human monoclonal antibody that binds to the integrin human IgG2 monoclonal antibody specific for human RANKL
GPIIb/IIIa receptor on activated platelets and inhibits fibrinogen, von - Binding RANKL it inhibits the maturation of osteoclasts, the cells
Willebrand factor, and other adhesion molecules from binding to responsible for bone resorption
activated platelets, thus preventing their aggregation postmenopausal women with osteoporosis at high risk for fracture.
Eculizumab Palivizumab
humanized IgG monoclonal antibody that binds the C5 complement monoclonal antibody that binds to the fusion protein of respiratory
component, inhibiting its cleavage into C5a and C5b thereby inhibiting syncytial virus, preventing infection in susceptible cells in the airways
the terminal pore-forming lytic activity of complement.
Ranibizumab
recombinant human IgG1 Fab that binds to VEGF-A
prevents new blood vessel formation by blocking VEGF from binding
to its receptor